204 related articles for article (PubMed ID: 26759624)
1. Dexlansoprazole - a new-generation proton pump inhibitor.
Skrzydło-Radomańska B; Radwan P
Prz Gastroenterol; 2015; 10(4):191-6. PubMed ID: 26759624
[TBL] [Abstract][Full Text] [Related]
2. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Fass R; Frazier R
Therap Adv Gastroenterol; 2017 Feb; 10(2):243-251. PubMed ID: 28203282
[TBL] [Abstract][Full Text] [Related]
3. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
Wittbrodt ET; Baum C; Peura DA
Clin Exp Gastroenterol; 2009; 2():117-28. PubMed ID: 21694835
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
[TBL] [Abstract][Full Text] [Related]
5. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.
Goh KL; Choi MG; Hsu PI; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Shetty V; Bocobo JC; Chan MM; Lin JT
J Neurogastroenterol Motil; 2016 Jul; 22(3):355-66. PubMed ID: 26932927
[TBL] [Abstract][Full Text] [Related]
7. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
8. Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR.
Frye JW; Peura DA
Ther Clin Risk Manag; 2015; 11():1649-56. PubMed ID: 26586949
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
10. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
11. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
Oldfield EC; Parekh PJ; Johnson DA
Expert Rev Gastroenterol Hepatol; 2016 Oct; 10(10):1083-1089. PubMed ID: 27580358
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
Mermelstein J; Mermelstein AC; Chait MM
Clin Exp Gastroenterol; 2016; 9():163-72. PubMed ID: 27471402
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
14. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Behm BW; Peura DA
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
[TBL] [Abstract][Full Text] [Related]
17. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
[TBL] [Abstract][Full Text] [Related]
18. Dexlansoprazole MR: a review.
Hershcovici T; Jha LK; Fass R
Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]